1315 Capital
1315 Capital is a private equity firm exclusively focused on growth-stage healthcare companies.
- Healthcare and life sciences private equity investment firm
- Healthcare & Life Sciences PEF
- Tier III
Overview
1315 Capital is a private equity firm exclusively focused on growth-stage healthcare companies. Its investment areas include healthcare services, pharmaceutical and medtech products, outsourced pharmaceutical and medtech services, and health and wellness.
The firm partners with commercial-stage businesses that have established products or services but require capital and operating support to accelerate growth. Its model is relevant to companies that may be beyond venture financing yet remain too early or specialized for traditional large-cap buyouts. Within The Economy Wiki, the firm is connected to the Healthcare & Life Sciences PEF market category.
Firm facts
| Institution | 1315 Capital |
| Type | Healthcare and life sciences private equity investment firm |
| Headquarters | Philadelphia, United States |
| Founded | 2014 |
| Primary ranking focus | Healthcare & Life Sciences PEF |
| Highest 2026 tier | Tier III |
Activities and investment capabilities
1315 supports portfolio companies through management resources, strategic initiatives, operational improvement, and commercial expansion. Its experience across products, services, and outsourcing provides useful breadth within a healthcare-only mandate.
Healthcare investing
Equity investment across healthcare services, products and technology.
Life sciences exposure
Capital for pharmaceutical, biotechnology, medtech and outsourced-service platforms.
Sector value creation
Support informed by regulation, reimbursement, clinical workflows and market access.
Strategy and transaction coverage
Strategy and sector coverage
Healthcare services; life sciences; pharmaceuticals; medtech; diagnostics; healthcare IT
Transaction and ownership contexts
Buyouts; growth investments; recapitalizations; platform formation; add-on acquisitions
Market position
1315 Capital fits Tier III because it is an increasingly developed healthcare growth platform with more than $1 billion under management, a clear specialist identity, and strong alignment with commercial-stage healthcare company building.
1315 Capital is assessed within the Healthcare & Life Sciences PEF framework. For wider market context, see The Mid-Market Advantage in Healthcare Private Equity.
Competitive context
1315 Capital is recognized Tier III in Top 30 Healthcare & Life Sciences PEF 2026. The ranking compares firms by institutional relevance, specialist capability, investment activity, operating depth and market positioning. Comparable-firm links below support navigation and do not imply that every institution competes for every transaction or asset.
Leadership and governance
Leadership, investment-committee composition and operating resources may change over time. Current information should be confirmed through 1315 Capital’s official website.
| Leadership area | Current source |
|---|---|
| Investment and operating leadership | Current team and governance information |
Corporate and public information
This profile refers to 1315 Capital as the public-facing investment organization. Individual funds, management companies, advisers and regulated entities may use separate legal names across jurisdictions.
Corporate and disclosure information
| Organization | 1315 Capital |
| Headquarters | Philadelphia, United States |
| Public website | 1315capital.com |
| Profile basis | Public institutional information and Capital Ranking editorial research |
Ranking recognition
Related Economy analysis
Selected Economy Markets articles provide context for the investment, diligence, financing and value-creation themes relevant to this firm:
- The Mid-Market Advantage in Healthcare Private Equity
- Middle-Market Private Equity: Returns, Scale and Manager Selection
- Private Equity Technology Due Diligence in the AI Era
